Table 1. Safety comparison between PVRV and PCECV with Zagreb or Essen regimen on different age group.

				Age groups for PVRV					Age groups for PCECV					P
				<5	5∼18	19∼60	>60	Total	<5	5∼18	19∼60	>60	Total
Zagreb	Patients Number			16	19	32	17	84	21	26	33	31	111	0.539d
	Local AEsa			4	9	3	7	23	4	4	4	12	24	0.352c
		Pain		2	8	2	6	18	1	3	3	9	16
		Induration		2	1	0	1	4	2	0	0	0	2
		Edema		0	0	1	0	1	0	0	0	1	1
		Tenderness		0	0	0	0	0	1	1	1	1	4
	Systemic AEsb			8	2	2	2	14	12	4	2	3	21	0.685c
		Fever (°C)		7	1	1	1	10	9	1	1	1	12	0.039
			37.1∼37.5	5	1	0	0	6	1	0	0	0	1
			37.6∼39.0	2	0	0	1	3	7	1	1	1	10
			>39.0	0	0	1	0	1	1	0	0	0	1
		Malaise		0	1	1	0	2	0	1	1	2	4
		Allergy		0	0	0	0	0	1	1	0	0	2
Essen	Patients Number			18	18	28	17	81	26	25	33	27	111	0.900d
	Local AEsa			3	7	2	4	16	4	10	3	8	25	0.644c
		Pain		1	5	0	2	8	0	7	2	5	14
		Induration		1	1	0	1	3	2	1	0	1	4
		Edema		0	0	1	1	2	1	1	1	1	4
		Tenderness		1	1	1	0	3	0	1	0	1	2
	Systemic AEsb			6	2	1	2	11	10	2	1	2	15	0.989c
		Fever (°C)		5	2	1	1	9	6	1	1	1	9	0.494c
			37.1∼37.5	4	1	0	0	5	2	1	0	0	3
			37.6∼39.0	1	1	1	1	4	4	1	1	1	7
			>39.0	0	0	0	0	0	0	0	0	0	0
		Malaise		0	0	0	1	1	0	1	0	1	2
		Allergy		0	0	0	0	0	2	0	0	0	2

^aLocal adverse events (AEs) included pain, induration, edema, tendemess, and erythema in this study, but only top 4 AEs were listed.

^bSystemic AEs included fever, malaise, allergy, restlessness, nausea and vomiting in this study, but only top 3 AEs were listed.

^cBy χ² test for comparison of total patients with AEs between PVRV and PCECV.

^dBy χ² test for comparison of patients number in different age groups between PVRV and PCECV.